ABSTRACT
Ependymomas account for 10% of all malignant pediatric central nervous system tumors. Standard therapy includes maximal safe surgical resection, followed by focal radiation. Despite the aggressive therapy, progression-free survival is poor. Most ependymoma relapses occur locally at the original tumor site. Extraneural presentations of ependymoma are extremely rare, and no standard of care treatment exists. We present a single-institution case series of 3 patients who experienced extraneural relapses of supratentorial ependymoma and describe their treatment and outcome. These cases of extraneural relapse highlight the possible modes of extraneural spread, including hematogenous, lymphatic, and microscopic seeding through surgical drains and shunts. In addition, they illustrate the increase in histologic grade and mutational burden that may occur at the time of relapse. These cases illustrate the role of aggressive, individualized treatment interventions using a combination of surgery, radiation, and chemotherapy.
Subject(s)
Ependymoma , Neoplasm Recurrence, Local , Humans , Child , Ependymoma/pathology , Combined Modality TherapySubject(s)
Epigenesis, Genetic/genetics , Neoplasms, Neuroepithelial/pathology , Receptor, Fibroblast Growth Factor, Type 2/genetics , Adolescent , Adult , Brain Neoplasms/genetics , Child, Preschool , DNA Methylation , Epilepsy/etiology , Epilepsy/genetics , Female , Humans , Male , Oncogene Proteins, Fusion , Young AdultABSTRACT
Three related males presented with a newly recognized x-linked syndrome associated with neurodegeneration, cutaneous abnormalities, and systemic iron overload. Linkage studies demonstrated that they shared a haplotype on Xp21.3-Xp22.2 and exome sequencing was used to identify candidate variants. Of the segregating variants, only a PIGA mutation segregated with disease in the family. The c.328_330delCCT PIGA variant predicts, p.Leu110del (or c.1030_1032delCTT, p.Leu344del depending on the reference sequence). The unaffected great-grandfather shared his X allele with the proband but he did not have the PIGA mutation, indicating that the mutation arose de novo in his daughter. A single family with a germline PIGA mutation has been reported; affected males had a phenotype characterized by multiple congenital anomalies and severe neurologic impairment resulting in infantile lethality. In contrast, affected boys in the family described here were born without anomalies and were neurologically normal prior to onset of seizures after 6 months of age, with two surviving to the second decade. PIGA encodes an enzyme in the GPI anchor biosynthesis pathway. An affected individual in the family studied here was deficient in GPI anchor proteins on granulocytes but not erythrocytes. In conclusion, the PIGA mutation in this family likely causes a reduction in GPI anchor protein cell surface expression in various cell types, resulting in the observed pleiotropic phenotype involving central nervous system, skin, and iron metabolism.
Subject(s)
Genetic Diseases, X-Linked/genetics , Germ-Line Mutation , Heredodegenerative Disorders, Nervous System/genetics , Iron Overload/genetics , Membrane Proteins/genetics , Spasms, Infantile/genetics , Amino Acid Sequence , Amino Acid Substitution , Autopsy , Base Sequence , Biopsy , Brain/pathology , Brain/ultrastructure , DNA Mutational Analysis , Facies , Fatal Outcome , Genes, X-Linked , Genetic Diseases, X-Linked/diagnosis , Heredodegenerative Disorders, Nervous System/diagnosis , Humans , Infant , Iron Overload/diagnosis , Kidney/pathology , Liver/pathology , Lymphocytes/ultrastructure , Magnetic Resonance Imaging , Male , Membrane Proteins/chemistry , Molecular Sequence Data , Pedigree , Sequence Alignment , Skin/pathology , Spasms, Infantile/diagnosis , Spleen/pathology , SyndromeABSTRACT
Myxopapillary ependymoma (MPE) is a rare subtype of ependymoma in children. Though classified as a Grade I tumor, their unpredictable behavior and propensity for local and disseminated recurrence poses a therapeutic challenge. Till date no predictive molecular markers exist for such recurrence, especially with dissemination. We demonstrated that Epidermal Growth Factor Receptor (EGFR) expression was seen in relapsed MPE both at diagnosis and at recurrence and none in the nonrecurring tumors. This finding suggests EGFR could be a predictive biomarker for recurrence in MPE.
Subject(s)
Biomarkers, Tumor/analysis , Central Nervous System Neoplasms/diagnosis , Ependymoma/diagnosis , ErbB Receptors/analysis , Central Nervous System Neoplasms/pathology , Ependymoma/secondary , Female , Humans , Inhibitor of Apoptosis Proteins/analysis , Male , Neoplasm Recurrence, Local/diagnosis , Prognosis , Survivin , Ubiquitin-Protein Ligases/analysisABSTRACT
Denys-Drash syndrome, characterized by nephrosis, dysgenetic gonads and a predisposition to Wilms tumor, is due to germline mutations in the WT1 gene. We report the pathologic findings on monozygotic twins, both of whom presented with male pseudohermaphroditism, nephrotic syndrome, and progressed to renal failure and death within the first month of life. Sequence analysis of WT1 demonstrated a G-to-A substitution in exon 8 of the gene (c.1097G > A), resulting in an arginine-to-histidine (R366H) substitution in the second zinc finger domain. To the best of our knowledge, this is only the second set of monozygotic twins with Denys-Drash syndrome reported to date.
Subject(s)
Denys-Drash Syndrome/genetics , Point Mutation , Renal Insufficiency/genetics , Twins, Monozygotic , WT1 Proteins/genetics , Denys-Drash Syndrome/pathology , Denys-Drash Syndrome/physiopathology , Disorder of Sex Development, 46,XY/genetics , Fatal Outcome , Female , Humans , Male , Nephrotic Syndrome/genetics , Nephrotic Syndrome/pathology , Renal Insufficiency/pathology , Renal Insufficiency/physiopathology , Wilms Tumor/genetics , Wilms Tumor/pathologyABSTRACT
The recognition of pulmonary manifestations of inflammatory bowel disease (IBD) is important as these diseases can be confused with infectious etiologies (e.g., tuberculosis or fungal infection) and, as a result, may unnecessarily delay institution of appropriate therapy (e.g., infliximab). Furthermore, they are a source of morbidity that may be overlooked and, like other IBD-related pathologies, are often responsive to treatment with corticosteroids, immunomodulators, or biologic therapies. The purpose of this paper is to describe the cases of six children at a single institution with differing presentations, treatments, and responses to treatment of their IBD-related lung disease to improve recognition of this uncommon process.
ABSTRACT
Despite progress in defining genetic risk for psychiatric disorders, their molecular mechanisms remain elusive. Addressing this, the PsychENCODE Consortium has generated a comprehensive online resource for the adult brain across 1866 individuals. The PsychENCODE resource contains ~79,000 brain-active enhancers, sets of Hi-C linkages, and topologically associating domains; single-cell expression profiles for many cell types; expression quantitative-trait loci (QTLs); and further QTLs associated with chromatin, splicing, and cell-type proportions. Integration shows that varying cell-type proportions largely account for the cross-population variation in expression (with >88% reconstruction accuracy). It also allows building of a gene regulatory network, linking genome-wide association study variants to genes (e.g., 321 for schizophrenia). We embed this network into an interpretable deep-learning model, which improves disease prediction by ~6-fold versus polygenic risk scores and identifies key genes and pathways in psychiatric disorders.
Subject(s)
Brain/metabolism , Gene Expression Regulation , Mental Disorders/genetics , Datasets as Topic , Deep Learning , Enhancer Elements, Genetic , Epigenesis, Genetic , Epigenomics , Gene Regulatory Networks , Genome-Wide Association Study , Humans , Quantitative Trait Loci , Single-Cell Analysis , TranscriptomeABSTRACT
Gardner fibroma (GAF) is a benign soft tissue lesion with a predilection for childhood and adolescence and an association with familial adenomatous polyposis (FAP) and desmoid type fibromatosis (desmoid). We report 45 patients with GAF with clinicopathologic correlation and immunohistochemical analysis for beta-catenin and related proteins. Forty-five patients with 57 GAFs were identified from surgical pathology and consultation files. Immunohistochemistry for beta-catenin, cyclin-D1, and C-myc was performed on formalin-fixed, paraffin-embedded tissues using standard techniques in 25 GAFs from 24 patients. Information about family history, intestinal polyps, colon cancer, and soft tissue tumors was available in 23 patients. Sixty-nine percent had known FAP or adenomatous polyposis coli (APC), 22% had no history of familial polyps or soft tissue tumors, and 13% had an individual or family history of soft tissue masses and/or desmoids, with follow-up periods of 6 months to 26 years (median 3 y, mean 5 y). The age range at initial diagnosis was 2 months to 36 years. Seventy-eight percent were diagnosed in the first decade, 15% in the second decade, and 7% in the third decade. Eight patients (18%) had documented desmoids concurrently or later; 4 of these had FAP and 1 had familial desmoids. Sites of GAF included the back and paraspinal region in 61%, the head and neck in 14%, the extremities in 14%, and the chest and abdomen in 11%. All displayed a bland hypocellular proliferation of haphazardly arranged coarse collagen fibers with a bland hypocellular proliferation of inconspicuous spindle cells, small blood vessels, and a sparse mast cell infiltrate. Immunohistochemically, 64% showed nuclear reactivity for beta-catenin (9 patients with known APC, 5 without definite information about FAP). One hundred percent showed nuclear reactivity for both cyclin-D1 and C-myc. beta-catenin reactivity had no correlation with age, site, or recurrence. Two beta-catenin-negative GAFs were from FAP patients. In conclusion, GAF has a predilection for childhood and early adulthood, a strong association with FAP/APC, an association with concurrent or subsequent development of desmoids, and overexpression of beta-catenin and other proteins in the APC and Wnt pathways. The proportion of sporadic GAFs that have APC mutation remains to be determined.
Subject(s)
Fibroma/pathology , Gardner Syndrome/pathology , Soft Tissue Neoplasms/pathology , Adenomatous Polyposis Coli/complications , Adenomatous Polyposis Coli/metabolism , Adenomatous Polyposis Coli/pathology , Adolescent , Adult , Biomarkers, Tumor/metabolism , Cell Nucleus/metabolism , Cell Nucleus/pathology , Child , Child, Preschool , Cyclin D , Cyclins/metabolism , Female , Fibroma/complications , Fibroma/metabolism , Fibromatosis, Aggressive/complications , Fibromatosis, Aggressive/metabolism , Fibromatosis, Aggressive/pathology , Gardner Syndrome/complications , Gardner Syndrome/metabolism , Humans , Immunohistochemistry , Infant , Male , Proto-Oncogene Proteins c-myc/metabolism , Soft Tissue Neoplasms/complications , Soft Tissue Neoplasms/metabolism , beta Catenin/metabolismABSTRACT
Timely communication of significant or unexpected findings in surgical pathology can significantly improve patient care. Although surgical pathology critical values have been published, no systematic assessment in pediatric surgical pathology has been published. We surveyed pediatric pathologists and pediatric subspecialists to develop pediatric surgical pathology critical values for verbal reporting before the final pathology report. A policy and process for reporting and documentation was implemented, with retrospective and prospective quality review. Critical values cases constituted 9.4% of surgical pathology accessions. Retrospective analysis revealed that 80% (73/91) had been reported and documented before policy implementation. Following implementation, 97.3% (402/413) were verbally reported and documented. A multidisciplinary group provided valuable information about critical values that might not have been obvious to pediatric pathologists but are important for patient care. Although the term critical values has become embedded in the surgical pathology literature, we would propose an alternative term for significant or unexpected findings that require timely communication and documentation.
Subject(s)
Hospitals, Pediatric , Pathology, Clinical/standards , Pathology, Surgical/standards , Pediatrics , Adolescent , Child , Clinical Laboratory Information Systems , Hospital Communication Systems , Humans , Infant , Interdisciplinary Communication , Reference StandardsABSTRACT
Central nervous system atypical teratoid/rhabdoid tumor (AT/RT) and choroid plexus carcinoma (CPC) are rare, highly malignant tumors that predominantly arise in infants and young children. Overlapping clinical, histologic, ultrastructural, or immunophenotypic features may obscure the diagnosis in some cases. AT/RT is characterized by deletions and/or mutations of the INI1 tumor-suppressor gene on chromosome band 22q11.2. We have recently developed an INI1 immunohistochemical staining assay. Negative staining of tumor cells resulting from inactivation of the INI1 gene is a consistent feature of AT/RT. Mutations of INI1 in some CPCs have been reported. The purpose of the present study was to determine if immunohistochemical staining with an INI1 antibody would provide a sensitive means of distinguishing between CPC and AT/RT. We examined 28 tumors with a submitted diagnosis of CPC. Twenty-one CPCs showed retained expression of INI1 and seven tumors showed loss of INI1 expression. Cytogenetic, FISH, and/or INI1 mutation results were also available for 13 tumors. In three of the seven cases, monosomy 22 was the only cytogenetic abnormality, suggestive of AT/RT. However, monosomy 22 was also identified in 3 tumors with complex karyotypes that retained INI1 expression. The 7 tumors that were immunonegative for INI1 had features that were consistent with AT/RT. Immunostaining for INI1 protein is retained in the majority of CPC and is lost in AT/RT. This expression pattern seems to better define the 2 groups of tumors than does light or electron microscopy, routine immunohistochemistry, or cytogenetic analysis alone.
Subject(s)
Biomarkers, Tumor/metabolism , Carcinoma/metabolism , Choroid Plexus Neoplasms/metabolism , DNA-Binding Proteins/metabolism , Gene Expression Regulation, Neoplastic/physiology , Teratoma/metabolism , Adolescent , Apoptosis , Biomarkers, Tumor/genetics , Carcinoma/pathology , Child , Child, Preschool , Choroid Plexus Neoplasms/pathology , Chromosomal Proteins, Non-Histone , DNA-Binding Proteins/genetics , Female , Humans , Immunohistochemistry/methods , In Situ Hybridization/methods , Infant , Male , Mucin-1/metabolism , SMARCB1 Protein , Staining and Labeling/methods , Teratoma/pathology , Transcription FactorsABSTRACT
Dramatic improvements in survival for children with cancer have led to increased numbers of posttreatment pathologic specimens, particularly in bone and soft tissue sarcomas. Current therapeutic protocols in North America require specific pathologic classification and stratify patients based on clinical, biologic, and pathologic features. For osteosarcoma, the pathologic response to therapy predicts prognosis and modifies the treatment regimen. Ongoing studies aim to assess the response to therapy and outcome in other types of soft tissue and bone tumors. The pathologic evaluation of pretreatment and posttreatment specimens is critical for therapeutic decisions and prognostic assessment. A standardized approach to posttherapy pathologic specimens, with attention to appropriate use of ancillary tests, and assessment of clinical and biologic significance of therapy-induced pathologic changes has significance for patient management and treatment protocols.
Subject(s)
Bone Neoplasms/therapy , Soft Tissue Neoplasms/therapy , Child , Fibrosarcoma/therapy , Humans , Neuroectodermal Tumors, Primitive/therapy , Osteosarcoma/therapy , Rhabdomyosarcoma/therapy , Sarcoma, Ewing/therapy , Sarcoma, Synovial/therapyABSTRACT
This study investigates differences in expression of the cell cycle/growth activation markers p53, p16, and p27, and their relationship with nerve sheath cell and proliferation markers among plexiform neurofibromas (PNF), NF1-related and non-NF1 MPNSTs of different histologic grades and between benign-appearing and malignant areas in the MPNSTs associated with PNFs. Formalin-fixed, paraffin-embedded archival tissue from PNFs and MPNSTs were immunostained using the avidin-biotin-complex method with antibodies to S-100 protein (S-100), Leu7 (CD57), CD34, p16, p27, p53, Mib-1, and topoisomerase II-alpha (TopoIIalpha), with appropriate controls. All PNFs and most low-grade MPNSTs displayed diffuse or focal reactivity for S-100, Leu7, CD34, p16, and p27 and negative reactivity for p53, Mib-1, and TopoIIalpha. Most high-grade MPNSTs displayed decreased or negative reactivity to S-100, Leu7, CD34, p16, and p27 but increased reactivity to p53 (59%), Mib-1 (72%), and TopoIIalpha (72%). In addition, combined nuclear and cytoplasmic (nucleocytoplasmic) p27 staining, which was not seen in the PNF or low-grade MPNST, was observed in 33% of high-grade MPNSTs. These findings suggest that p53, p16, and p27 may be involved in tumor progression in the PNF-MPNST sequence. However, alterations in p53, p16, and p27 do not distinguish between low-grade MPNST and PNF, including PNF adjacent to high-grade MPNST. Although p53, p16, and p27 are unlikely to be reliable markers for early detection of tumor progression in MPNST, p53 reactivity was more frequent in NF1-associated high-grade MPNST and appeared to be a marker for high tumor grade. Combining immunohistochemical stains with histologic grading with careful examination of mitotic activity may provide insight into the progression of peripheral nerve sheath tumors.
Subject(s)
Biomarkers, Tumor/analysis , Cell Cycle Proteins/biosynthesis , Nerve Sheath Neoplasms/chemistry , Nerve Sheath Neoplasms/pathology , Adolescent , Adult , Cell Cycle/physiology , Cell Cycle Proteins/analysis , Cell Division/physiology , Cell Transformation, Neoplastic , Child , Female , Humans , Immunohistochemistry , Male , Nerve Sheath Neoplasms/complications , Neurofibromatosis 1/complicationsABSTRACT
Congenital melanocytic nevi (CMN) occur in 1% to 2% of newborns, and the risk of malignant melanoma is increased in patients with large CMN. Appearance at birth or later of a nodular or hyperpigmented area within a CMN simulates malignant melanoma and prompts biopsy. Although their clinical and pathologic features seem ominous, proliferative nodules (PNs) typically are benign and may regress, although atypical features cause greater concern. Here we report clinical and pathologic findings with outcome in 10 children who had multiple biopsies of large CMN with PNs. We reviewed 78 separate samples from the 10 patients and classified the 60 PNs according to published criteria. A subset of 30 samples containing both the CMN and a PNs was analyzed for immunohistochemical reactivity for melanocytic (S-100 protein, HMB45, melan-A), lymphocytic (CD45), cell-cycle/proliferative (Mib-1, p16, p21, p27, c-Myc), apoptotic (p53, Bax, c-kit, CD95), and anti-apoptotic (bcl-2) markers. Both CMN and PNs had similar expression of melanocytic, lymphocytic, and most cell-cycle/proliferative and apoptotic markers, including Mib-1, p16, p21, p27, c-Myc, Bax, CD95, and bcl-2. A greater proportion of PNs than CMN were reactive for p53 (67% vs. 30%, P < 0.0098) and c-kit (97% vs. 3%, P < 0.0001). p53 and p21 expression in CMN and all types of PNs were inversely correlated. When ordinary and atypical PNs were compared, the atypical PNs more frequently expressed p53, Mib-1, Bax, and bcl-2, but less frequently expressed p21. The c-kit expression in nearly all PNs and its absence in nearly all CMN is potentially useful for recognition of PN, suggests a delayed melanocytic maturation process in proliferative nodules, and may be likely indicative of their benign nature. p53 reactivity in concert with a lack of p21 up-regulation by immunohistochemistry suggests that a p53 mutation may be present in PN, although the immunohistochemical findings alone cannot exclude possible overexpression of wild-type p53. Regressive, involutional, or maturational changes were observed in sequential samples from 4 patients. No patient developed malignant melanoma or another melanocytic nevus-associated malignancy during the follow-up period. These findings underscore the similarities between PNs and the underlying CMN and suggest that maturational, proliferative, and apoptotic processes are involved in their clinical evolution.
Subject(s)
Melanocytes/pathology , Nevus, Pigmented/pathology , Precancerous Conditions/pathology , Skin Neoplasms/pathology , Apoptosis , Biomarkers, Tumor/metabolism , Cell Division , Cell Nucleus/metabolism , Cell Nucleus/pathology , Female , Humans , Immunohistochemistry , Infant , Infant, Newborn , Male , Melanocytes/metabolism , Nevus, Pigmented/congenital , Nevus, Pigmented/metabolism , Precancerous Conditions/congenital , Precancerous Conditions/metabolism , Retrospective Studies , Skin Neoplasms/congenital , Skin Neoplasms/metabolismABSTRACT
We report a case of pleuropulmonary blastoma with complex cytogenetic abnormalities, including trisomy 2, trisomy 8, dup(7), der(10) t(8; 10)(q13; q22), add(17), and double minutes (dmin). Fluorescence in situ hybridization FISH analysis demonstrated TP53 deletion and amplification of MYCN; the latter has not been reported in PPB.
Subject(s)
Chromosome Aberrations , Chromosomes, Human , Lung Neoplasms/genetics , Nuclear Proteins/genetics , Oncogene Proteins/genetics , Pulmonary Blastoma/genetics , Child, Preschool , Cytogenetic Analysis , Female , Gene Deletion , Humans , In Situ Hybridization, Fluorescence , Lung Neoplasms/drug therapy , Lung Neoplasms/pathology , N-Myc Proto-Oncogene Protein , Pulmonary Blastoma/drug therapy , Pulmonary Blastoma/pathology , Trisomy , Tumor Suppressor Protein p53/geneticsABSTRACT
This case report involved male infants of a size consistent with the estimated gestational age of 31 weeks. The mother of the twins was a 27-year-old, G4P3 woman with limited prenatal care who presented for cesarean delivery. Resuscitation efforts were initiated and continued until the infants became asystolic. Postmortem radiographs showed innumerable fractures of the limbs, ribs, and skull in various states of healing with callus formation; hence, the fractures were of prenatal origin. Despite the fractures, the growth of the long bones was not impaired. The radiographic findings were initially thought to represent osteogenesis imperfecta type IIC. However, there were also vascular anomalies not explained by this phenotype. Grossly, all arteries were elongated, thickened, and tortuous. The carotids, descending aorta, and iliac arteries were redundant to such an extent that they produced corkscrew patterns. There was also cutis laxa with loose, redundant skin over the entire body. Collagen genes did not show any mutations; however, when it was suggested Fibulin-4 be studied because of overlap with the condition described by Dasouki and colleagues in 2007, a homozygous premature stop codon mutation was found in that gene.
Subject(s)
Abnormalities, Multiple/genetics , Arteries/abnormalities , Extracellular Matrix Proteins/genetics , Mutation , Adult , Cutis Laxa/genetics , Female , Homozygote , Humans , Male , Osteogenesis Imperfecta/pathology , Pregnancy , Twins, MonozygoticABSTRACT
The detection of chromosomal translocations has important implications in the diagnosis, prognosis and treatment of patients with cancer. Current approaches to translocation detection have significant shortcomings, including limited sensitivity and/or specificity, and difficulty in application to formalin-fixed paraffin-embedded (FFPE) clinical samples. We developed a new approach called antibody detection of translocations (ADOT) that avoids the shortcomings of current techniques. ADOT combines a transcriptional microarray-based approach with a novel antibody-based detection method. ADOT allows for the accurate and sensitive identification of translocations and provides exon-level information about the fusion transcript. ADOT can detect translocations in poor-quality unprocessed total ribonucleic acid (RNA). Furthermore, the technique is readily generalizable to detect any potential fusion transcript, including previously undescribed fusions. We demonstrate the feasibility of ADOT by examples in which both known and unknown Ewing sarcoma translocations are identified from cell lines, tumour xenografts and FFPE primary tumours. These results demonstrate that ADOT may be an effective approach for translocation analysis in clinical specimens with significant RNA degradation and may offer a novel diagnostic tool for translocation-based cancers.
Subject(s)
Antibodies , Pathology, Molecular/methods , Sarcoma, Ewing/pathology , Translocation, Genetic , Animals , Gene Fusion , Humans , Mice , Mice, Nude , Microarray Analysis/methods , Sensitivity and Specificity , Transcription, GeneticABSTRACT
Ewing sarcoma (ES) is the second most common bone tumor in children and young adults, with dismal outcomes for metastatic and relapsed disease. To better understand the molecular pathogenesis of ES and to identify new prognostic markers, we used molecular inversion probes (MIPs) to evaluate copy number alterations (CNAs) and loss of heterozygosity (LOH) in formalin-fixed paraffin-embedded (FFPE) samples, which included 40 ES primary tumors and 12 ES metastatic lesions. CNAs were correlated with clinical features and outcome, and validated by immunohistochemistry (IHC). We identified previously reported CNAs, in addition to SMARCB1 (INI1/SNF5) homozygous loss and copy neutral LOH. IHC confirmed SMARCB1 protein loss in 7-10% of clinically diagnosed ES tumors in three separate cohorts (University of Utah [N = 40], Children's Oncology Group [N = 31], and University of Michigan [N = 55]). A multifactor copy number (MCN)-index was highly predictive of overall survival (39% vs. 100%, P < 0.001). We also identified RELN gene deletions unique to 25% of ES metastatic samples. In summary, we identified both known and novel CNAs using MIP technology for the first time in FFPE samples from patients with ES. CNAs detected by microarray correlate with outcome and may be useful for risk stratification in future clinical trials.
Subject(s)
Bone Neoplasms/genetics , Gene Dosage , Molecular Probes , Sarcoma, Ewing/genetics , Adolescent , Adult , Bone Neoplasms/pathology , Cell Adhesion Molecules, Neuronal/genetics , Child , Child, Preschool , Chromosomal Proteins, Non-Histone/genetics , DNA-Binding Proteins/genetics , Extracellular Matrix Proteins/genetics , Female , Gene Deletion , Humans , Immunohistochemistry , Infant , Loss of Heterozygosity , Male , Nerve Tissue Proteins/genetics , Paraffin Embedding , Reelin Protein , SMARCB1 Protein , Sarcoma, Ewing/pathology , Serine Endopeptidases/genetics , Transcription Factors/genetics , Young AdultSubject(s)
Conjunctival Neoplasms/pathology , Rhabdomyosarcoma/pathology , Child, Preschool , Combined Modality Therapy , Conjunctival Neoplasms/chemistry , Conjunctival Neoplasms/therapy , Desmin/analysis , Female , Humans , Immunoenzyme Techniques , Magnetic Resonance Imaging , Myogenin/analysis , Rhabdomyosarcoma/chemistry , Rhabdomyosarcoma/therapyABSTRACT
Oligodendroglioma is an uncommon childhood tumor and is more chemosensitive than other malignant glial neoplasms. Treatment involves gross total resection, and if anaplastic, radiation and chemotherapy. Distinct genetic alterations are associated with improved prognosis. We report a child with a low-grade oligodendroglioma that recurred as a high-grade oligodendroglioma and ultimately as extraneural systemic relapse. It was initially responsive to temozolomide, cyclophosphamide, etoposide, and carboplatin, perhaps predicted by combined loss of heterozygosity at 1p and 19q. This chemotherapy may be promising in treating malignant oligodendroglioma. However, he succumbed to progressive systemic disease. Positron emission spectroscopy scan was useful in sequentially assessing his disease.
Subject(s)
Brain Neoplasms/diagnosis , Neoplasm Recurrence, Local/diagnosis , Oligodendroglioma/diagnosis , Pleural Neoplasms/diagnosis , Adolescent , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Brain Neoplasms/genetics , Brain Neoplasms/therapy , Disease Progression , Fatal Outcome , Humans , Magnetic Resonance Imaging/methods , Male , Neoplasm Recurrence, Local/genetics , Neoplasm Recurrence, Local/therapy , Oligodendroglioma/genetics , Oligodendroglioma/therapy , Pleural Effusion, Malignant/diagnosis , Pleural Effusion, Malignant/therapy , Pleural Neoplasms/secondary , Pleural Neoplasms/therapy , Positron-Emission Tomography/methods , RecurrenceABSTRACT
We describe a case of inflammatory myofibroblastic tumor with an unusual constellation of clinical, pathologic, and genetic findings. A 7-year-old girl had an 11-cm abdominopelvic mass accompanied by thrombocytosis, anemia, elevated erythrocyte sedimentation rate, and elevated C-reactive protein. The inflammatory myofibroblastic tumor displayed unusual histologic features of zonal coagulative necrosis, high cellularity with a herringbone pattern, and tumor-associated osteoclast-like giant cells. The complex tumor karyotype included a translocation t(1;2)(q21; p23). Following resection, the laboratory abnormalities resolved. The patient is well and free of recurrence at 3 years following resection. This case raises interesting questions about clinical, pathologic, prognostic, and molecular genetic interrelationships in inflammatory myofibroblastic tumor.